CAR enters July with a striking internal contradiction: short sellers pulled back sharply over the week, yet options traders are the most defensive they have been in months.
The stock dropped 22% on the week to $147.83, adding to a 16% loss over the past month. That kind of price action would normally attract fresh shorts. Instead, short interest fell 15% on the week to roughly 16.4% of the free float — a meaningful unwind from the ~19% level that prevailed in mid-June. The direction of travel is notable. Bears who had been piling in through most of June appear to have covered into the sell-off, not added. The ORTEX short score of 68 is elevated in absolute terms but has drifted lower from its mid-June peak near 69.2, consistent with that covering trend.
The borrow market tells a more nuanced story. Availability has loosened from very tight levels — it reached a 52-week low of just 0.07% earlier this year — and is currently at around 68%, which is tight but no longer extreme. Cost to borrow jumped 72% on the week to just over 1%, a sharp move in percentage terms, though still modest in absolute terms. That spike suggests new demand for borrows arrived even as the aggregate short count fell, possibly reflecting fresh entrants replacing covered positions rather than a uniform exit. Days to cover, per the FINRA fortnightly data, sits at 8.8 days — the queue to exit remains substantial.
Options positioning has turned markedly more defensive than usual. The put/call ratio is running at 1.80, well above its 20-day average of 1.57, placing it about 1.2 standard deviations above the mean. More striking is the directional shift: the PCR sat in the 1.37-1.51 range through most of May and early June before jumping sharply above 1.80 around June 22 — exactly when the stock broke lower. That cluster of put buying has not unwound. The 52-week high on the PCR is 2.85, so there is room for the defensive posture to deepen further.
The analyst community remains largely bearish, but has been moving targets upward even while maintaining cautious ratings. JP Morgan kept its Underweight but raised its target to $170 on June 23 — a recent move that now places the stock below the JP Morgan target for the first time in weeks, given the sell-off. Barclays upgraded to Equal-Weight from Underweight on June 8 with a $160 target. With the stock now at $147.83, the consensus mean target of $134 is actually below the current price, suggesting the Street's formal targets have not kept pace with the move in either direction and are of limited near-term utility. Factor scores reflect the tension: analyst recommendation divergence ranks in the 93rd percentile versus peers — an unusually wide spread of views — while the short score rank sits in just the 7th percentile, meaning the borrow market characterises CAR as one of the more heavily shorted names in the universe. The stock's Altman Z-score of 0.62, flagged in recent ORTEX score analysis, keeps balance-sheet risk in the conversation alongside every trading narrative.
Institutional ownership adds a layer of context worth noting. Pentwater Capital, which held a 10%+ stake, sold over $230 million worth of shares on April 23 at prices between $264 and $290 — levels the stock has since abandoned entirely. UBS Asset Management remains the largest holder at 12.5% of shares. The management-level insider register shows only minor executive sells from late April at prices around $183, also well above current levels. The concentrated selling at higher prices, combined with the stock's continued decline, has left the shareholder base reshuffling at materially lower valuations.
Next quarter's earnings are due July 31. The recent pattern has been volatile: a 4.4% one-day gain after Q1 results, but a nearly 7% drop the prior quarter, with five-day moves reaching as wide as -19%. Whether the current PCR elevation and residual short position of 16.4% of float compress or expand into that date is the setup worth tracking.
See the live data behind this article on ORTEX.
Open CAR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
